europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

What if we could definitively cure AIDS

26/01/2020
FACTSHEET
What if we could definitively cure AIDS

This might be possible in the future by going into the DNA and deleting the AIDS-causing virus

Promise: A combination of antiviral therapy and genome editing has succeeded in removing the HIV virus from infected mice.

Did you know?
Globally, more than 5000 people are infected by HIV every day. Curing people of HIV would impede its spread and bring us closer to achieving the third UN Sustainable Development Goal of Good Health and Well-Being.

UNAIDS estimates that in 2018 more than 36.7 million people worldwide were infected with the human immunodeficiency virus type one (HIV-1). This virus causes acquired immune deficiency syndrome (AIDS), which breaks down the immune system and makes patients susceptible to infections and cancers. Depending on the type of HIV, patients have on average 9 to 11 years to live after infection. Antiviral treatment can extend life expectancy, but does not cure the disease itself.

That could change in the future, though. In July 2019, scientists at Temple University and the University of Nebraska succeeded in eliminating HIV-1 from living animals using CRISPR genome editing. CRISPR/Cas9 is a protein used for precision genetic engineering that allows scientists to change or delete individual letters of the genetic code with high efficiency and relative ease. Because viruses integrate themselves into the genome of their host, curing the HIV infection requires cutting them out of the DNA in all the infected cells. The approach followed by the researchers consists in combining a long-acting, slow release antiviral therapy with CRISPR/Cas9 delivery to the body’s cells. The antiviral therapy subdues the infection and CRISPR removes the DNA. In this combination, it successfully cuts out the DNA from infected immune cells in living mice. The virus can no longer be found in the blood, lymphoid tissue, bone marrow, or brain. This new approach will hopefully soon be replicated in clinical trials. This is potentially lifesaving news for millions of people.

What if we could definitively cure AIDS


Download
2020_01_H_F_EuropaBIO_WHATIF_AIDS_V04Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more
01/03/2023

Vlad Olteanu new Healthcare Public Affairs Director at EuropaBio


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies